48,851
edits
Difference between revisions of "Cancer antigen 125"
Jump to navigation
Jump to search
→Positive or negative
| Line 11: | Line 11: | ||
==Positive or negative== | ==Positive or negative== | ||
*[[Cholangiocarcinoma]] +ve/-ve (30 +ve of 63 cases<ref name=pmid22286058>{{Cite journal | last1 = Higashi | first1 = M. | last2 = Yamada | first2 = N. | last3 = Yokoyama | first3 = S. | last4 = Kitamoto | first4 = S. | last5 = Tabata | first5 = K. | last6 = Koriyama | first6 = C. | last7 = Batra | first7 = SK. | last8 = Yonezawa | first8 = S. | title = Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. | journal = Pathobiology | volume = 79 | issue = 2 | pages = 101-6 | month = | year = 2012 | doi = 10.1159/000335164 | PMID = 22286058 }}</ref>) | *[[Cholangiocarcinoma]] +ve/-ve (30 +ve of 63 cases<ref name=pmid22286058>{{Cite journal | last1 = Higashi | first1 = M. | last2 = Yamada | first2 = N. | last3 = Yokoyama | first3 = S. | last4 = Kitamoto | first4 = S. | last5 = Tabata | first5 = K. | last6 = Koriyama | first6 = C. | last7 = Batra | first7 = SK. | last8 = Yonezawa | first8 = S. | title = Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. | journal = Pathobiology | volume = 79 | issue = 2 | pages = 101-6 | month = | year = 2012 | doi = 10.1159/000335164 | PMID = 22286058 }}</ref>). | ||
==Usually negative== | ==Usually negative== | ||